glp-1 risk factors Obesity and cardiovascular disease consensus statement Long-term Success of GLP-1s Hinges

With the rise in use of GLP-1 drugs, health insurers must balance these drugs proven effectiveness with the cost of treatment

said on May 2 that it gained exclusive development and commercial rights to Hangzhou, China-based Sciwind Biosciences Co

Background and Aim The association between biliary disorders with weight reduction enhanced by GLP-1RAs was observed frequently, nevertheless, the relative risk of the clinically relevant cholelithiasis was not specified clearly among different GLP-1RAs

Obesity is a pandemic problem that correlates with a cluster of metabolic factors leading to poor cardiovascular outcomes, morbidity, and an increased risk of overall mortality

FDA Concerns Surrounding Compounded GLP-1 In a May 16, 2025 statement, the U.S